ProMIS Neurosciences Announces Retention of Mackie Research Capital Corporation as Market Maintenance Service Provider

TORONTO, July 15, 2016 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it has retained Mackie Research Capital Corporation ("Mackie") to provide market maintenance services for the company in compliance with regulatory guidelines. Mackie will trade shares of ProMIS on the TSX for the purposes of maintaining a reasonable market and improving the liquidity of ProMIS's shares.

The agreement is for a twelve month period and may be terminated at any time by ProMIS or Mackie. There are no performance factors contained in the agreement and Mackie will not receive any shares or options from ProMIS as compensation for the services it will render. ProMIS and Mackie are unrelated and unaffiliated entities, but Mackie may provide investment banking services to ProMIS and Mackie and/or its clients may have an interest, directly or indirectly, in the securities of ProMIS.

About Mackie Research Capital Corporation
Mackie is one of Canada's largest independent full service investment firms, and proudly traces its roots back to 1921. Mackie is privately owned by many of its 300 employees. As a fully integrated national investment dealer, Mackie offers a full complement of capital markets and wealth management services to private clients, institutions and growth companies.

For further information, please contact Adam Smith at: 416-860-7654

About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS^™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

SOURCE ProMIS Neurosciences Inc.

NATIONAL Equicom, Michael Moore: [email protected], Abby Garfunkel: [email protected]; or contact: Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. [phone], [email protected]